Amburanjan Santra1, Rakesh Kumar2. 1. Department of Nuclear Medicine, Brain imaging Centre, Dakshi Diagnostics, Lucknow, Uttar Pradesh, India. 2. Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India.
Abstract
Brain single photon emission computed tomography (SPECT) is a well-established and reliable method to assess brain function through measurement of regional cerebral blood flow (rCBF). It can be used to define a patient's pathophysiological status when neurological or psychiatric symptoms cannot be explained by anatomical neuroimaging findings. Though there is ample evidence validating brain SPECT as a technique to track human behavior and correlating psychiatric disorders with dysfunction of specific brain regions, only few psychiatrists have adopted brain SPECT in routine clinical practice. It can be utilized to evaluate the involvement of brain regions in a particular patient, to individualize treatment on basis of SPECT findings, to monitor the treatment response and modify treatment, if necessary. In this article, we have reviewed the available studies in this regard from existing literature and tried to present the evidence for establishing the clinical role of brain SPECT in major psychiatric illnesses.
Brain single photon emission computed tomography (SPECT) is a well-established and reliable method to assess brain function through measurement of regional cerebral blood flow (rCBF). It can be used to define a patient's pathophysiological status when neurological or psychiatric symptoms cannot be explained by anatomical neuroimaging findings. Though there is ample evidence validating brain SPECT as a technique to track human behavior and correlating psychiatric disorders with dysfunction of specific brain regions, only few psychiatrists have adopted brain SPECT in routine clinical practice. It can be utilized to evaluate the involvement of brain regions in a particular patient, to individualize treatment on basis of SPECT findings, to monitor the treatment response and modify treatment, if necessary. In this article, we have reviewed the available studies in this regard from existing literature and tried to present the evidence for establishing the clinical role of brain SPECT in major psychiatric illnesses.
Brain single photon emission computed tomography (SPECT) is a well-established and reliable method for evaluating brain function through measurement of regional cerebral blood flow (rCBF).[1] It is being utilized for detection of various neurodegenerative diseases and their management for several years. Brain SPECT can be used to define a patient's pathological status when neurological or psychiatric symptoms cannot be explained by structural neuroimaging findings. Though there is ample evidence in the literature validating brain SPECT as a promising technique to track human behavior and correlating psychiatric disorders with dysfunction of specific brain regions, it is rarely utilized technique in routine psychiatric practice. Renowned medical bodies like the American College of Radiology, the Society of Nuclear Medicine and the European Society of Nuclear Medicine have published evidence-based guidelines for using brain SPECT to improve patient care. Commonly accepted clinical indications for brain SPECT include: Dementia (early diagnosis, differentiation from normal ageing, and differential diagnosis of Alzheimer's disease from other neurodegenerative diseases), epilepsy (localization of epileptic focus by ictal and interictal studies), movement disorders, traumatic brain injury, cerebrovascular diseases, brain tumor and brain infections.[234] Nearly two decades back, Holman and Devous in their study, highlighted brain SPECT as a powerful window into the function of the brain and asserted it as a promising tool which could become an important component of the routine clinical evaluation of patients with neurological and psychiatric diseases.[5] A consistently growing body of research supports brain SPECT's clinical utility. In 1996, Vasile concluded that, the clinical utility of SPECT in neuropsychiatry is well-established.[6] Camargo reviewed the utility of brain SPECT in 2001 and demonstrated its role in obsessive-compulsive disorder (OCD), Gilles de la Tourette's syndrome, schizophrenia, depression, panic disorder, and drug abuse, in addition to common neurological indications.[7] However, despite the evidence relevant to diagnosis and treatment, only few psychiatrists have adopted brain SPECT or other functional neuroimaging techniques in routine clinical practice. Brain SPECT can be utilized to evaluate the involvement of specific brain regions in different patients, to individualize the treatment, for monitoring the treatment response and to modify treatment, when warranted. Though specific perfusion patterns for various psychiatric diseases have not been definitely recognized, perfusion and receptor imaging findings may be used as an additional diagnostic tool to guide clinicians searching for a definitive diagnosis. In this review article we have tried to consolidate the facts from existing literature and our own clinical experience, as to the kind of role brain SPECT can play in different psychiatric diseases.
BRAIN PERFUSION SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY-TECHNICAL OVERVIEW
Radiopharmaceuticals
The tracers used for brain perfusion SPECT are technetium- 99m- hexamethylpropyleneamineoxime (99mTc-HMPAO) and technetium-99m-ethylcysteinate dimer (99mTc-ECD). The main differences between 99mTc-HMPAO and 99mTc-ECD relate to their in vitro stability, uptake mechanism, and dosimetry.[8910] 99mTc-HMPAO is highly unstable in vitro and high radiochemical purity must be assured before injection.[11] Stabilized forms of 99mTc-HMPAO allow easier labeling and improvement of image quality by reducing background activity.[12] By contrast, 99mTc-ECD is stable up to at least 4 h in vitro, and freshly eluted 99mTc is not required. Higher gray-matter-to-white-matter ratio, contributes to the better image quality obtained with 99mTc-ECD. Although both of tracers are distributed proportionally to rCBF, their retention is not completely linear with rCBF because of an initial back diffusion. High blood flow may be underestimated and low blood flow may be overestimated with both tracers.[1314] In normal brain tissue, the kinetic properties are similar for both the perfusion agents. They enter the brain cells because of their lipophilic nature and remain there because of conversion into hydrophilic compounds. However, in patients with brain disease, the distribution of these compounds may differ because of the biochemistry of lipophilic-to-hydrophilic conversion. Although a metabolic process of de-esterification accounts for hydrophilic conversion of 99mTc-ECD, instability of the lipophilic form have been proposed for 99mTc-HMPAO. A perfusion-metabolic (de-esterification) coupling is needed in case of 99mTc-ECD to be trapped within cell, whereas only perfusion matters in 99mTc-HMPAO. Thus, 99mTc-ECD would have a predominant cellular-metabolic uptake, and 99mTc-HMPAO would reflect blood flow arrival to cerebral regions.[15]
Patient preparation
Before arrival, patients should be instructed to avoid, if possible, caffeine, alcohol, or other drugs known to affect cerebral blood flow (CBF). Brain perfusion is sensitive to neuronal activities, hence, tracer injection to be done in a quiet room and no interaction with patients at this time is desirable, to avoid any sensorial and cognitive stimuli. To avoid head movement during scanning (20-30 min), the patient should be comfortable and relaxed. The uncooperative patients (those with severe cognitive impairment or with loss of insight) may need sedation. Tracer injection must precede sedation to avoid sedation-induced blood flow changes. Appropriate positioning is needed to keep the collimators as close as possible to the patient's head and to get entire brain within the center of field of view.[1617]
Acquisition system and postprocessing software
Because of the small size of important anatomically and functionally independent cerebral structures, spatial resolution is the main concern in brain imaging. A good compromise is to fit a general purpose rotating camera with fan beam collimator. Addition of computed tomography scan improves the quality of images by attenuation correction and structural correlation. Software applications are available for image processing to quantify the results in terms of rCBF for each brain functional area. Many of them have the features to compare with normal population database and provide statistical parametric mapping, so that one can easily recognize the abnormally perfused area.[1617]
MAJOR PSYCHIATRIC DISORDERS AND BRAIN PERFUSION SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY
Attention deficit hyperactivity disorder
Attention deficit hyperactivity disorder (ADHD) is one of the most prevalent disorders in child and adolescent psychiatry. Prevalence of ADHD in the general population is approximately 5% of school-age children.[18] ADHD is characterized by a developmentally inappropriate poor attention span or age-inappropriate features of hyperactivity and impulsivity or both. To meet the Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) diagnostic criteria, the disorder should be present for at least 6 months, cause impairment in academic or social functioning, and occur before the age of 7 years. ADHD appears to be heterogeneous, with a variety of known etiologies such as head trauma, intrauterine exposure to toxins, and infections, but in the majority of cases no etiology can been determined.[19] A neurobiological basis of ADHD resulting from the involvement of the fronto-striatal system has been proposed.[20] Several studies [Table 1] analyzed the patterns of rCBF in ADHD, demonstrating decreases in brain perfusion, especially in the premotor cortex and the prefrontal cortex, and hypoperfusion of striatal and periventricular structures.[21222324] Daniel et al. found that, 65% of children and adolescents with ADHD revealed decreased perfusion in the prefrontal cortex with intellectual stress, though only 25% had decreased prefrontal lobe activity at rest.[25] There is a pattern of lateralization in prefrontal hypoperfusion from right to left with increase in age of patients as demonstrated by a study.[26] Many researcher demonstrated temporal lobe dysfunction as significant in patients with ADHD. Kaya et al. described temporal hypoperfusion being more frequent than in the frontal cortex.[27] An association of temporal lobe hypoperfusion with severity of symptoms and comorbidity have been demonstrated by some studies.[2728] Studies were also undertaken to demonstrate the response to methylphenidate treatment. Responders usually normalize the prefrontal hypoperfusion and may have increase or decrease in striatal perfusion.[2930] The nonresponders had significantly increased activity in anterior cingulated (AC) cortex at baseline.[31] We observed both prefrontal and temporal hypoperfusion in all of the seven ADHDpatients scanned in our center [Figure 1] and there is evidence of prefrontal activity normalization in available post therapy scans (four out of seven in a time period of 6-9 months) after successful treatment.
Table 1
Review summary of brain perfusion studies in patients with ADHD
Figure 1
Technetium-99m-hexamethylpropyleneamineoxime brain perfusion single photon emission computed tomography-computed tomography (SPECT-CT) images of a 17 year old attention deficit hyperactivity disorder patient, showing hypoperfusion in bilateral frontal cortices and bilateral medial temporal lobes. (a) Transverse view, (b) sagittal view, (c) coronal view of the SPECT-CT, (d) right lateral, (e) left lateral surface projection views of “Neurogam” processed (compared with normal population adult database) images with color scale below (d and e)
Review summary of brain perfusion studies in patients with ADHDTechnetium-99m-hexamethylpropyleneamineoxime brain perfusion single photon emission computed tomography-computed tomography (SPECT-CT) images of a 17 year old attention deficit hyperactivity disorderpatient, showing hypoperfusion in bilateral frontal cortices and bilateral medial temporal lobes. (a) Transverse view, (b) sagittal view, (c) coronal view of the SPECT-CT, (d) right lateral, (e) left lateral surface projection views of “Neurogam” processed (compared with normal population adult database) images with color scale below (d and e)
Obsessive-compulsive disorder
Obsessive-compulsive disorder is rare (5% of psychiatricpatients), with a usually gradual onset in adolescence or early adult life and a slightly greater prevalence in females. Family history shows a high incidence in other members. Obsessions are imperative, distressing thoughts that persist despite the desire to resist them and may take various forms: Intellectual (phrases, rhymes, ideas, images), impulsive (killing, stabbing, performing abject acts), or inhibiting. Compulsions are acts that result from obsessions, such as checking rituals, repeated hand washing, and wiping objects. Brain SPECT findings in patients with OCD have been investigated by several authors [Table 2]. A study suggested involvement of prefrontal-striatal-thalamic and limbic circuitry in the pathophysiology of OCD.[32] Hyperperfusion of the anterior portion of the cingulate gyrus; bilateral orbito-frontal regions; and in some patients, basal ganglia, before therapy has been described.[333435] These changes returned to normal after treatment with fluoxetine.[3435] In contrast, hypoperfusion of the frontal lobes, right caudate nucleus, and right thalamus has also been found.[36] Patients with poor insight on their condition or with schizo-obsessive behavior probably will display hypoperfusion of the frontal lobes, whereas patients with adequate insight tend to display hyperperfusion of frontal lobes and cingulate gyrus. Impulsive issues are often from low activity in the prefrontal cortex and compulsive tendencies are usually due to high activity in the anterior cingulate gyrus. In our patients, we observed hypoperfusion of prefrontal, temporal and AC cortex in majority, probably due to our study group, which comprises chronic patients under long term treatment [Figure 2]. Anterior cingulate cortex seems to be an important structure in the pathogenesis of OCD symptoms and anterior cingulotomy is an approach for symptomatic improvement.[37] The patients having increased activity in frontal and AC cortex also respond well to selective serotonin reuptake inhibitors.[3839] There is possible role of brain SPECT in tracking hereditary OCD or predicting future development of OCD in offspring.[40]
Table 2
Review summary of important brain perfusion study findings in patients with OCD
Figure 2
Technetium-99m-hexamethylpropyleneamineoxime brain perfusion single photon emission computed tomography (SPECT) in a 40-year-old male patient with obsessive-compulsive disorder revealed hypoperfusion in bilateral prefrontal cortices, with right temporal and occipital lobe. (a) Transverse view, (b) sagittal view, (c) coronal view of the SPECT images
Review summary of important brain perfusion study findings in patients with OCDTechnetium-99m-hexamethylpropyleneamineoxime brain perfusion single photon emission computed tomography (SPECT) in a 40-year-old male patient with obsessive-compulsive disorder revealed hypoperfusion in bilateral prefrontal cortices, with right temporal and occipital lobe. (a) Transverse view, (b) sagittal view, (c) coronal view of the SPECT images
Schizophrenia
Schizophrenia comprises a group of closely related disorders characterized by a particular type of disordered affect, behavior, and thinking. Symptoms are usually categorized as positive (auditory, tactile, visual, or olfactory hallucinations; persecutory, grandiose, or religious delusions; aggressiveness; bizarre appearance; abnormal sexual behavior; disordered thoughts) or negative (poor eye contact, speech, or hygiene; inappropriate affect; blocking; apathy; social inattentiveness). Though there is conflict among several studies [Table 3], brain SPECT most frequently shows hypofrontality, especially during a specific task; perfusion changes in the basal ganglia, possibly related to the use of neuroleptic drugs; and temporal lobe hypoperfusion, usually on the left side and frequently associated with ipsilateral frontal lobe hypoperfusion[41] [Figure 3]. However, patients who are not receiving medication may show hyperfrontality and depending on positive or negative symptoms may show conflicting findings (hypo and hyperperfusion).[42] Patients with positive symptoms have demonstrated increased precuneus activity.[43] Hypofrontality and temporal hypoperfusion related with negative symptoms and aggression in schizophrenia.[4445464748] Studies on treatment response evaluation demonstrated improvement of blood flow in frontal, temporal, basal ganglia region with increased activity in motor cortex.[49505152] Involvement of inferior parietal cortex, cuneus and posterior temporal lobe are noted in chronic and progressive disease.[53] Injection of perfusion agents at the time of visual or auditory hallucinations shows hyperperfusion of the primary visual or auditory cortex, respectively.[54] Cognitive activation also significantly increases frontal activity in schizophrenia cases.[55] We have studied >50 patients of chronic schizophrenia and found significant hypoperfusion in prefrontal cortex mainly dorsolateral prefrontal cortex, and orbitofrontal cortex (OFC), temporal lobe, mainly temporopolar and superior temporal cortex, and inferior parietal lobule. There was also involvement of basal ganglia in 50% cases with occasional involvement of cerebellum, and sometimes global hypoperfusion [Figure 4] in severe cases.
Table 3
Review summary of important brain perfusion study findings in patients with schizophrenia
Figure 3
A 45-year-old female with paranoid schizophrenia on antipsychotic treatment have bilateral frontal, and temporal hypoperfusion in technetium-99mhexamethylpropyleneamineoxime brain perfusion single photon emission computed tomography-computed tomography images. (a) Transverse view, (b) sagittal view, (c) coronal view
Figure 4
A 26-year-old male with disorganized schizophrenia was under treatment for last 1-year, showing global cortical hypoperfusion with relative increase in basal ganglia and cerebellar activity in technetium-99m-hexamethylpropyleneamineoxime brain perfusion single photon emission computed tomography-computed tomography images. (a) Transverse view, (b) sagittal view, (c) coronal view
Review summary of important brain perfusion study findings in patients with schizophreniaA 45-year-old female with paranoid schizophrenia on antipsychotic treatment have bilateral frontal, and temporal hypoperfusion in technetium-99mhexamethylpropyleneamineoxime brain perfusion single photon emission computed tomography-computed tomography images. (a) Transverse view, (b) sagittal view, (c) coronal viewA 26-year-old male with disorganized schizophrenia was under treatment for last 1-year, showing global cortical hypoperfusion with relative increase in basal ganglia and cerebellar activity in technetium-99m-hexamethylpropyleneamineoxime brain perfusion single photon emission computed tomography-computed tomography images. (a) Transverse view, (b) sagittal view, (c) coronal view
Anxiety and depression
Anxiety and depression are extremely common public health problems in today's world. The loss to our society from these illnesses is staggering: Individual pain, family strife, school and relationship failure, lost work productivity, and death. People actively seek out a cure for anxiety and depression, and are put on prescription medications that can harm them in other ways. Loss of interest or pleasure is the key symptom of depression. Other symptoms include feelings of hopelessness, worthlessness, and emotional pain; reduced energy and motivation; trouble sleeping; decreased appetite; and weight loss.[56] Brain SPECT with perfusion agents in patients free of medication has shown hypoperfusion of the following areas: The prefrontal area and temporal lobes, cingulate gyrus, and left caudate nucleus.[575859] There is evidence of prefrontal, limbic, and paralimbic hypoperfusion in both unipolar and bipolar depression;[60] and the lateral frontal area involvement in acute depression in the elderly.[61] Hypofrontality was shown to be associated with severe negative symptoms[62] [Figure 5]. In many occasions, both anxiety and depression coexist. Increased activity in the basal ganglia and frontal lobe may be seen in patients with anxiety [Figure 6]. Severity of depression is inversely correlated with rCBF in left cingulate cortex, lentiform nucleus, and parahippocampal gyrus, and directly correlated with right posterolateral parietal cortex. Anxiety directly correlated with right anterolateral OFC, while cognitive performance correlated with right posteromedial OFC and left lentiform nucleus.[6364] Cognitive decline in postmenopausal women is also associated with hypofrontality.[65] In major depressive disorders, sadness is related to decrease activity in dorsolateral prefrontal and dorsal cingulated cortex, with increased activity in ventromedial prefrontal and ventral cingulated cortex; whereas anxiety is associated with left AC cortex.[66] Whole brain blood flow also correlated positively with anxiety.[67] When recurrent depressions progressed to melancholies, involvement of left posterior parieto-temporal region is seen in addition to hypofrontality.[68] Findings of brain SPECT in anxiety depression disorders from different studies are summarized in Table 4.
Figure 5
A 62-year-old female with severe depression, showing severe bilateral hypofrontality in technetium-99m-hexamethylpropyleneamineoxime brain perfusion single photon emission computed tomography (SPECT). (a) Transaxial and (b) saggital view brain SPECT of the patient
Figure 6
An 18-year-old male with severe anxiety neurosis revealed hyperactive prefrontal cortices and basal ganglia in technetium-99m-hexamethylpropyleneamineoxime brain perfusion single photon emission computed tomography images. (a) Transverse view, (b) sagittal view, (c) right lateral view of three-dimensional Talairach cortical perfusion report, (d) extracted basal ganglia and thalamus by “Neurogam” processing, (e) color scale for (c and d)
Table 4
Summary of important brain perfusion study findings in patients suffering from anxiety-depression disorder
A 62-year-old female with severe depression, showing severe bilateral hypofrontality in technetium-99m-hexamethylpropyleneamineoxime brain perfusion single photon emission computed tomography (SPECT). (a) Transaxial and (b) saggital view brain SPECT of the patientAn 18-year-old male with severe anxiety neurosis revealed hyperactive prefrontal cortices and basal ganglia in technetium-99m-hexamethylpropyleneamineoxime brain perfusion single photon emission computed tomography images. (a) Transverse view, (b) sagittal view, (c) right lateral view of three-dimensional Talairach cortical perfusion report, (d) extracted basal ganglia and thalamus by “Neurogam” processing, (e) color scale for (c and d)Summary of important brain perfusion study findings in patients suffering from anxiety-depression disorder
Substance abuse and addiction
Psychoactive substance abuse and dependence are disorders defined by patterns of maladaptive behavior related to the procurement and ingestion of substances of abuse (marijuana, hallucinogens, inhalants, cocaine, crack, heroin, stimulants, alcohol, and others).[69] Short and long-term substance abuse affects blood flow and metabolism, which negatively affect the way our central nervous system works [Table 5]. Fortunately, some researchers report that the damage associated with chronic use of alcohol, nicotine, inhalants, and solvents is at least partially reversible with de-addiction treatment. Brain SPECT, has shown disseminated CBF defects in abusers of cocaine, crack, heroin and alcohol.[707172737475] [Figures 7 and 8]. Disappearance or improvement of the defects after a period of abstinence has been described, suggesting that arterial spasms may cause the defects.[70717475] Some studies in cocaine abusers described abnormality in the OFC and superior temporal cortex, with evidence of minute differences between men and women.[7677] Patients with a history of inhalation of industrial solvents, such as glue, paint, and gasoline, have similar perfusion abnormalities.[78]
Table 5
Summary of important brain perfusion study findings in patients suffering from substance abuse disorders
Figure 7
A 19-year-old female with multiple substance abuse disorder (predominantly alcohol and organic solvent) with induced-withdrawal behavioral problem showing diffuse cortical hypoperfusion on both side of cerebral cortex. (a) Transverse view, (b) sagittal view, (c) coronal view of technetium-99m-hexamethylpropyleneamineoxime brain single photon emission computed tomography, (d) right lateral, (e) left lateral surface projection views of “Neurogam” processed (compared with normal population adult database) images with color scale below (d and e)
Figure 8
A 41-year-old male with multiple substance abuse disorder with significant decline in social and occupational performance showing severely decreased cortical perfusion globally. (a) Transverse view, (b) sagittal view, (c) coronal view of technetium-99m-hexamethylpropyleneamineoxime brain single photon emission computed tomography
Summary of important brain perfusion study findings in patients suffering from substance abuse disordersA 19-year-old female with multiple substance abuse disorder (predominantly alcohol and organic solvent) with induced-withdrawal behavioral problem showing diffuse cortical hypoperfusion on both side of cerebral cortex. (a) Transverse view, (b) sagittal view, (c) coronal view of technetium-99m-hexamethylpropyleneamineoxime brain single photon emission computed tomography, (d) right lateral, (e) left lateral surface projection views of “Neurogam” processed (compared with normal population adult database) images with color scale below (d and e)A 41-year-old male with multiple substance abuse disorder with significant decline in social and occupational performance showing severely decreased cortical perfusion globally. (a) Transverse view, (b) sagittal view, (c) coronal view of technetium-99m-hexamethylpropyleneamineoxime brain single photon emission computed tomography
Autism spectrum disorders
Autism spectrum disorders (ASD) are diagnosed today more than ever before. It has incidence rate of 2-5/10,000 births, males 1.5 times more commonly affected than females. This disorder is an early and severe development disorder, characterized by deficits in verbal and nonverbal languages, social skills, cognitive functioning and abnormal repetition of behavior (DSM-III R criteria). All children, teens, and adults with ASD are individuals and have unique brain patterns-one size does not fit all when it comes to ASD. Though SPECT studies are normal in many of the autismpatients, it may show decreased temporal lobe perfusion. Up to 30% of autisticchildren eventually develop temporal lobe epilepsy.[79] A study by Degirmenci et al. suggested the existence of regional brain perfusion alterations in frontal, temporal, and parietal cortex and in caudate nucleus in autisticchildren and in their first-degree family member.[80]
SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY TO PERSONALISE TREATMENT IN PSYCHIATRIC DISORDERS
When brain SPECT scans detect the hyperfrontality pattern, it opens new avenues for intervention since this finding has been associated with predicting a positive treatment response to serotonergic medications in depression[38818283] and OCD,[8485] predicting a positive response to sleep deprivation[8687] and repetitive transcranial magnetic stimulation[88] for depression, predicting treatment response to a cingulotomy in OCD,[89] and help in distinguishing OCD from ADHD.[90] Hypofrontality, that is, decreased perfusion or activity in the prefrontal cortex, is another important brain SPECT finding that is often helpful in understanding and targeting treatment in individual patients. Hypofrontality is associated with a negative response to serotonergic medication in depression[91] and clozapine in schizophrenia[92] as well as with predicting relapse in alcoholics,[93] improved response to acetylcholine-esterase inhibitors for memory and behavior in AD,[9495] predicting a poor response to ketamine in fibromyalgiapatients[96] and improved response to stimulants in patients with ADHD symptoms during a concentration challenge.[97] Hypofrontality is also associated with antisocial symptoms, impulsive behaviors, and murder[98] as well as with completed suicide, which is often an impulsive act.[99] When hypofrontality is present in depressedpatients, it is important to be vigilant in their care, as well as involve family support, as they may be less likely to respond to typical antidepressant medications and they may not have the cognitive resources to follow through with recommendations.[100] When abnormalities in the temporal lobes are seen (either hypo or hyperperfusion) and mood instability or temper problems are present, anticonvulsants provide a rational treatment option.[101] If there are memory or learning issues (and low temporal lobe perfusion), acetylcholine-esterase inhibitors may be helpful,[102] always taking into consideration the clinical picture.
CONCLUSIONS
Brain perfusion SPECT is a valuable tool in management of psychiatric disorders. It has a role in the diagnosis, therapeutic management, and follow-up of these patients. In addition, brain SPECT is a useful tool for research, because it is widely available and provides noninvasive in vivo assessment of human brain function. We can use this tool in psychiatric practice to evaluate the involvement of brain regions in a patient for a particular clinical condition, can individualize the treatment on basis of brain SPECT findings, can monitor the treatment response and modify the treatment, if necessary. There are a number of important areas where brain SPECT has the potential to provide relevant information to help personalize treatment to patients’ specific brain system pathophysiology rather than rely solely on general diagnostic and/or therapeutic categories. Brain SPECT should always be evaluated in conjunction with clinical assessment since it adds value to routine clinical assessment.
Authors: A J Zametkin; L L Liebenauer; G A Fitzgerald; A C King; D V Minkunas; P Herscovitch; E M Yamada; R M Cohen Journal: Arch Gen Psychiatry Date: 1993-05
Authors: D A Seminowicz; H S Mayberg; A R McIntosh; K Goldapple; S Kennedy; Z Segal; S Rafi-Tari Journal: Neuroimage Date: 2004-05 Impact factor: 6.556
Authors: Fatemeh Adelnia; Michelle Shardell; Christopher M Bergeron; Kenneth W Fishbein; Richard G Spencer; Luigi Ferrucci; David A Reiter Journal: NMR Biomed Date: 2019-03-12 Impact factor: 4.044
Authors: Alexi Gosset; Hayley Wagman; Dan Pavel; Philip Frank Cohen; Robert Tarzwell; Simon de Bruin; Yin Hui Siow; Leonard Numerow; John Uszler; John F Rossiter-Thornton; Mary McLean; Muriel van Lierop; Zohar Waisman; Stephen Brown; Behzad Mansouri; Vincenzo Santo Basile; Navjot Chaudhary; Manu Mehdiratta Journal: Front Neurol Date: 2022-04-11 Impact factor: 4.086